Zevra Therapeutics, Inc.
Description
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
About
CEO
Mr. Neil F. McFarlane
Employees
65
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNGS
Address
1180 Celebration Boulevard, Celebration, FL 34747, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 10, 2025 | — | — | — | — |
| Aug 11, 2025 | — | — | — | — |
| May 6, 2025 | — | — | — | — |
| Mar 27, 2025 | — | — | — | — |
| Nov 13, 2024 | -0.42 | -0.69 | -0.27 | 64.29% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 5 | — | 7 |
| Average estimate | — | 0.48 | — | -0.04 |
| Low estimate | — | -0.30 | — | -1.33 |
| High estimate | — | 2.07 | — | 1.88 |
| Last year EPS | — | -0.40 | — | -1.93 |
[stock_revenue_estimate]
Growth estimates
Current qtr
0.360%
Next qtr. (Mar 2025)
221.000%
Current year
-48.570%
Next year (Dec 2025)
97.930%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | — | 10.16M | 28.65M | 13.29M | 12.84M |
| Cost of revenue | — | 222,000 | 2.06M | 1.31M | 2.95M |
| Gross profit | — | 9.94M | 26.59M | 11.98M | 9.89M |
| Operating expense | |||||
| Research & development | — | 19.80M | 10.16M | 8.84M | 19.42M |
| Selling general and admin | — | 15.04M | 8.70M | 7.92M | 10.82M |
| Other operating expenses | — | — | — | — | — |
| Operating income | — | -24.90M | 7.73M | -4.78M | -20.34M |
| Non operating interest income | |||||
| Income | — | 1.51M | 261,000 | 89,000 | 309,000 |
| Expense | — | 335,000 | 376,000 | 7.09M | 6.51M |
| Other income expense | — | -3.08M | -16.14M | -1.01M | 2.00M |
| Pretax income | — | -26.81M | -8.52M | -12.79M | -24.54M |
| Tax provision | — | -33,000 | 34,000 | -34,000 | -22,000 |
| Net income | — | -26.77M | -8.56M | -12.76M | -24.52M |
| Basic EPS | -1.30 | -1.20 | -2.11 | -3.21 | -13.28 |
| Diluted EPS | -1.30 | -1.20 | -2.11 | -3.21 | -13.28 |
| Basic average shares | 35.45M | 34.49M | 29.77M | 3.98M | 1.85M |
| Diluted average shares | 35.45M | 34.49M | 29.77M | 3.98M | 1.85M |
| EBITDA | — | -22.45M | 8.25M | -4.42M | -19.72M |
| Net income from continuing op. | — | -26.77M | -8.56M | -12.76M | -24.52M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | 54.34M | — | — |
Balance sheet
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Fiscal date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 115.34M | 132.94M | 11.21M | 10.51M | 26.75M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 65.47M | 112.35M | 4.21M | 3.22M | 18.41M |
| Other short term investments | 17.38M | — | — | — | 3.26M |
| Accounts receivable | 7.19M | 1.42M | 2.44M | 1.68M | — |
| Other receivables | 1.11M | 107,000 | 137,000 | 184,000 | 140,000 |
| Inventory | — | — | — | — | — |
| Prepaid assets | 577,000 | 930,000 | 1.28M | 516,000 | 1.91M |
| Restricted cash | — | — | 109,000 | 338,000 | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 1.11M | 252,000 | 203,000 | 231,000 | 1.91M |
| Non current assets | |||||
| Properties | 1.95M | 2.82M | 3.02M | 3.19M | 1.04M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 566,000 | 409,000 | 367,000 | 422,000 | 954,000 |
| Construction in progress | — | — | — | — | — |
| Leases | 710,000 | 724,000 | 724,000 | 958,000 | 1.02M |
| Accumulated depreciation | -1.44M | -1.93M | -1.73M | -1.56M | -1.25M |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | 20.00M | 15.42M | — | — | — |
| Other non current assets | 724,000 | 438,000 | 438,000 | 527,000 | 1.27M |
| Total liabilities | 40.22M | 5.82M | 77.62M | 84.96M | 93.31M |
| Current liabilities | |||||
| Accounts payable | 3.61M | 516,000 | 1.17M | 1.14M | 3.72M |
| Accrued expenses | 2.56M | 2.52M | 5.47M | 3.77M | 4.63M |
| Short term debt | 480,000 | 371,000 | 889,000 | 284,000 | 3.55M |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | — | — | — | — | — |
| Other current liabilities | 5.37M | 821,000 | 172,000 | 236,000 | 115,000 |
| Non current liabilities | |||||
| Long term debt | 13.64M | 1.24M | 69.66M | 79.24M | 78.50M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | 10.20M | 330,000 | 304,000 | 120,000 | 2.12M |
| Other non current liabilities | 4.35M | 25,000 | 123,000 | 168,000 | 689,000 |
| Shareholders equity | |||||
| Common stock | 3,000 | 4,000 | — | — | 3,000 |
| Retained earnings | -353.73M | -267.03M | -258.47M | -245.71M | -221.19M |
| Other shareholders equity | 113,000 | — | — | — | — |
| Total shareholders equity | 75.12M | 127.12M | -66.41M | -74.46M | -66.57M |
| Additional paid in capital | 436.27M | 396.96M | 192.06M | 171.26M | 154.62M |
| Treasury stock | 7.54M | 2.81M | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||
| Net Income | -26.77M | -8.56M | -12.76M | -24.52M | -56.47M | -43.39M | -16.52M | -54.66M | -24.46M | -5.23M |
| Depreciation | 944,000 | 257,000 | 273,000 | 304,000 | 324,000 | 336,000 | 175,000 | 84,000 | 75,000 | 68,000 |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 4.29M | 2.44M | 2.49M | 4.41M | 6.50M | 4.56M | 6.60M | 2.37M | 214,000 | 134,000 |
| Other Non-Cash Items | 17.89M | 460,000 | 7.25M | 3.19M | 3.71M | 3.84M | -28.63M | 31.86M | 2.72M | 1.71M |
| Accounts Receivable | -6.77M | 1.05M | -714,000 | -1.73M | — | — | — | — | — | — |
| Accounts Payable | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | 4.13M | 530,000 | 125,000 | -1.69M | -102,000 | 77,000 | 368,000 | — | — | — |
| Operating Cash Flow | -6.29M | -3.82M | -3.34M | -20.03M | -46.04M | -34.57M | -38.00M | -20.36M | -21.45M | -3.31M |
| Investing Activities | ||||||||||
| Capital Expenditures | -93,000 | -102,000 | -33,000 | -26,000 | -21,000 | -181,000 | -643,000 | -135,000 | -47,000 | -51,000 |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | -14.09M | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -23.86M | -15.42M | — | — | — | -27.38M | -89.85M | -19.00M | — | — |
| Sale of Investments | — | — | — | 3.26M | 33.35M | 54.97M | 44.65M | — | — | — |
| Investing Cash Flow | -38.04M | -15.52M | -33,000 | 3.23M | 33.33M | 27.41M | -46.95M | -19.14M | -42,000 | -34,000 |
| Financing Activities | ||||||||||
| Long-Term Debt Issuance | 12.80M | — | 781,000 | — | — | — | 82.80M | 4.00M | 25.00M | 3.85M |
| Long-Term Debt Payments | -16,000 | -38.10M | -227,000 | -207,000 | -193,000 | -157,000 | -20.63M | -32,000 | -66,000 | -58,000 |
| Other Financing Charges | -33,000 | 73.92M | -118,000 | -300,000 | -184,000 | -50,000 | -1.15M | -2.85M | -1.93M | -53,000 |
| Financing Cash Flow | 8.03M | 82.29M | 2.74M | 4.94M | 27.95M | -207,000 | 61.02M | 61.06M | 22.97M | 3.74M |
| Other Cash Details | ||||||||||
| End Cash Position | 65.47M | 112.35M | 4.32M | 3.56M | 19.12M | 11.97M | 17.86M | 32.32M | 10.26M | 1.97M |
| Income Tax Paid | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 321,000 | 218,000 | 78,000 | 5.36M | 5.54M | 5.72M | 3.29M | — | 3,000 | 5,000 |
| Free Cash Flow | -18.81M | 10.34M | -1.97M | -23.76M | -54.22M | -33.28M | -30.42M | -20.40M | -14.72M | -4.38M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 1,667,443 | 13.66M | 38.65% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 1,175,190 | 9.62M | 27.24% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 739,174 | 6.05M | 17.13% |
| Fidelity Advisor Equity Growth Fund | Nov 30, 2024 | 659,820 | 5.40M | 15.29% |
| Variable Insurance Products Fund-Growth Portfolio | Nov 30, 2024 | 642,100 | 5.26M | 14.88% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 428,981 | 3.51M | 9.94% |
| Fidelity Capital Appreciation Fund | Nov 30, 2024 | 414,700 | 3.40M | 9.61% |
| Fidelity Growth Discovery Fund | Nov 30, 2024 | 358,870 | 2.94M | 8.32% |
| Fidelity Extended Market Index Fund | Nov 30, 2024 | 271,777 | 2.23M | 6.30% |
| iShares Russell 2000 Growth ETF | Nov 30, 2024 | 208,317 | 1.71M | 4.83% |
Article
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™
Zevra to receive a 2025 New Treatment Award for MIPLYFFA™ at the 21 st Annual WORLDSymposium
Jan 30, 2025
Article
Zevra Therapeutics to Participate at Upcoming Investor Conferences
CELEBRATION, Fla., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage rare disease therapeutics company, today announced that members of Zevra's executive leadership team will participate in the following February events.
Jan 29, 2025
Article
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will take Accolade private.
Jan 8, 2025
